NEO
$49.34
Neogenomics
($.20)
(.40%)
NEO
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  ($0.01)
Revenue:  $113.71 Mil
Wednesday
May 5
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when NEO reports earnings?
Beat
Meet
Miss

Where is NEO's stock price going from here?
Up
Flat
Down
Stock chart of NEO
Analysts
Summary of analysts' recommendations for NEO
Score
Grade
Pivots
Resistance
$51.66
$50.98
$50.16

$49.48

Support
$48.66
$47.98
$47.16
Tweet
Growth
Description
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
Peers
IncyteAlexion PharmaceuticalsExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex